The Economist todayeradicated
. Only one disease, smallpox, has ever been eliminated. Instead, global immunity will increase as more people are vaccinated or contract covid-19. Some 3.8bn have had at least one jab and 2.8bn are fully vaccinated. Together with those who have caught the disease, around half the world’s population has some level of immunity. Eventually, covid-19 will become endemic: transmission will remain at a steady rate, following seasonal patterns, with fewer spikes in infection.
In the meantime, vaccines and treatments will continue to lower the burden of the disease. By the second half of 2022 there will probably be a
XeuleBot
We were there the moment the media coverage switched from death counts to case counts. Respiratory viruses of any type have a death toll. Regardless of vaccinations. People of all age groups succumb to these viruses. We don’t test as well as we do with cv-19. Live your lives.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here's How Many Daily COVID-19 Cases Might Get Us Back to ‘Normal,’ Per Dr. FauciPlus, how we make it happen.
Source: SELFmagazine - 🏆 478. / 51 Read more »
Moderna seeks U.S. authorization of COVID-19 booster shots for all adultsModerna Inc said on Wednesday it had applied with the U.S. Food and Drug Administration for authorization of its COVID-19 booster vaccine for all adults aged 18 and older.
Source: Reuters - 🏆 2. / 97 Read more »
Eating disorder hospitalizations doubled during COVID-19 pandemic, new data showsThe number of people who were hospitalized for eating disorders in the U.S. doubled during the COVID-19 pandemic, new research shows. SudanCoup
Source: ABC - 🏆 471. / 51 Read more »
U.S. looking to broaden access to COVID-19 antiviral pills - WSJThe administration is reviewing whether Paxlovid, the antiviral from Pfizer Inc, can be available on the commercial market in retail pharmacies if it gets regulatory clearance, the Journal reported. Molnupiravir, an oral pill from Merck & Co Inc and Ridgeback Biotherapeutics LP that is also under regulatory review, may be included in the government's plan to make it commercially available, the journal reported, citing the person. The United States has agreed to buy 10 million courses of Pfizer's drug and has so far secured 3.1 million courses of Merck's pill. 🤠 😎 😈 😇 🌍 👽 🌝 🌞 🌌 Всё зырит ж с Сотворильни ~ но ничему ~ не задивится уже Хаим ~ ДжО! « Гхлупость терпят за простодушие, но не наоборот.» ~ REMEMBER ABOUT SHOW~FUTURE ! ~ BELIEVE IN YOURSELF A LITTLE MORE ! ~ ФСЕ Ж ФУТЫ ПОД ЛЫЖНЁЙ ~ GOOD LUCK ! ! ! 👋🏻 )) ~
Source: YahooNews - 🏆 380. / 59 Read more »
Everything you need to know about getting a COVID-19 boosterMixing and matching is approved, and all adults are currently eligible for booster shots.
Source: TODAYshow - 🏆 389. / 55 Read more »
All U.S. Adults Can Now Get a COVID-19 Booster Shotthe FDA approved booster shots for everyone 18 and older who received their second dose of the Pfizer or Moderna vaccine at least six months ago. That headline seems misleading. Still need CDC approval? You are TEEN Vogue. Who is your audience?
Source: TeenVogue - 🏆 481. / 51 Read more »